Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination

Cancer Treatment Reviews
Daniel T Bergstralh, Jenny P-Y Ting

Abstract

Microtubule stabilization by chemotherapy is a powerful weapon in the war against cancer. Disruption of the mitotic spindle activates a number of signaling pathways, with consequences that may protect the cell or lead to its death via apoptosis. Taxol, the first microtubule stabilizing drug to be identified, has been utilized successfully in the treatment of solid tumors for two decades. Several features, however, make this drug less than ideal, and the search for next generation stabilizing drugs with increased efficacy has been intense and fruitful. Microtubule stabilizing agents (MSAs), including the taxanes, the epothilones, discodermolide, laulimalide, and eleutherobin, form an important and expanding family of chemotherapeutic agents. A strong understanding of their molecular signaling consequences is essential to their value, particularly in regard to their potential for combinatorial chemotherapy - the use of multiple agents to enhance the efficacy of cancer treatment. Here we present a critical review of research on the signaling mechanisms induced by MSAs, their relevance to apoptosis, and their potential for exploitation by combinatorial therapy.

References

Feb 22, 1979·Nature·P B SchiffS B Horwitz
Mar 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·P B Schiff, S B Horwitz
Sep 12, 1995·Proceedings of the National Academy of Sciences of the United States of America·A A ReszkaE H Fischer
Aug 30, 1994·Proceedings of the National Academy of Sciences of the United States of America·X M WangG G Borisy
Apr 1, 1993·Molecular and Cellular Biology·J PosadaJ A Cooper
Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G PagèsJ Pouysségur
Jan 1, 1996·Life Sciences·F J Dumont, Q Su
Jan 1, 1996·Annual Review of Immunology·A S Baldwin
Apr 21, 1997·The Journal of Cell Biology·X M WangJ E Ferrell
Aug 1, 1997·Nature Medicine·G AmbrosiniD C Altieri
Jan 13, 1998·Current Opinion in Cell Biology·P K SorgerA A Hyman
Feb 3, 1998·Molecular and Cellular Biology·J S Lanni, T Jacks
May 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·P J Moos, F A Fitzpatrick
Jan 1, 1995·Progress in Cell Cycle Research·A Koff, K Polyak
May 28, 1998·The Journal of Biological Chemistry·H Greulich, R L Erikson
Jun 12, 1998·The Journal of Cell Biology·J C WatersE D Salmon
Jan 23, 1999·Oncogene·E C LaCasseA E MacKenzie
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·R K SrivastavaD L Longo
Apr 10, 1999·Molecular Biology of the Cell·A M YvonM A Jordan
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·I OjimaS J Danishefsky
Apr 21, 1999·Current Opinion in Cell Biology·R Ohi, K L Gould
Jul 8, 1999·Nature Medicine·J S Sebolt-LeopoldA R Saltiel
Jul 21, 1999·Proceedings of the National Academy of Sciences of the United States of America·M J Martinez-ExpositoP K Sorger
Sep 2, 1999·International Journal of Cancer. Journal International Du Cancer·M V Blagosklonny, T Fojo

❮ Previous
Next ❯

Citations

Jan 10, 2009·Cancer Chemotherapy and Pharmacology·Carl F BeyerJames J Gibbons
Nov 13, 2009·Investigational New Drugs·Katherine MonaghanAndrew Spencer
Apr 22, 2010·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Ting ZhouShixuan Wang
Dec 27, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·M Gordaliza
Aug 9, 2007·Future Microbiology·Barbara Kappes, Petra Rohrbach
May 16, 2009·Expert Opinion on Therapeutic Patents·Ying ZhaoKlaus Pors
Dec 18, 2009·Expert Review of Anticancer Therapy·Debra K Frye
Dec 15, 2010·Expert Opinion on Investigational Drugs·Branislav Bystricky, Ian Chau
Jun 6, 2013·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Daniel Morales-CanoJosé C Diez
Mar 27, 2012·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Jui-Chuan ChuangMing-Fang Wu
Jul 14, 2010·Journal of Ethnopharmacology·Jürg GertschPeter Taylor
Nov 22, 2008·Bioorganic & Medicinal Chemistry·Ian PatersonAmy E Wright
Oct 28, 2008·Bioorganic & Medicinal Chemistry Letters·Ian PatersonAmy E Wright
Nov 14, 2008·Acta histochemica·Aleksandra StepienLidia Gackowska
Mar 29, 2007·Natural Product Reports·Karl-Heinz Altmann, Jürg Gertsch
Apr 15, 2008·Journal of Molecular Biology·J Torin HuzilDavid C Schriemer
Dec 11, 2007·Biochimica Et Biophysica Acta·Barbara T McGroganAmanda McCann
Jul 24, 2007·The Journal of Urology·Paul Mathew, Robert Dipaola
Feb 2, 2008·International Journal of Cancer. Journal International Du Cancer·Boris A HadaschikMartin E Gleave
Mar 14, 2008·Chembiochem : a European Journal of Chemical Biology·Lars BräuerLudger Wessjohann
Jan 18, 2007·Journal of Cellular Biochemistry·Yih-Huei UenShyr-Yi Lin
Nov 15, 2011·Journal of Ovarian Research·Anna Felisiak-GolabekUNKNOWN Polish Ovarian Cancer Study Group (POCSG)
Oct 6, 2009·Cancer Cell·Hsiao-Chun HuangTimothy J Mitchison
Aug 31, 2010·Journal of Molecular and Cellular Cardiology·Kun ZhangBarbara E Ehrlich
Mar 6, 2012·Biochemical and Biophysical Research Communications·Yasuyuki MorikawaKazuhiro Suzuki
Nov 22, 2014·PloS One·Joshua M EichhornTimothy C Chambers
Sep 7, 2016·Journal of Cancer Research and Clinical Oncology·Yang-Ling LiChong Zhang
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anirban P MitraRichard J Cote
Dec 3, 2008·Nature Clinical Practice. Oncology·James J Lee, W Kevin Kelly
Jul 9, 2009·The Annals of Pharmacotherapy·Laura Boehnke Michaud
Jun 5, 2019·Current Topics in Medicinal Chemistry·Yong-Tao DuanYongfang Yao
Oct 27, 2017·Oncotarget·Jadith ZieglerRheal A Towner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Caspases in Metabolic Diseases

Caspases, the family of cysteine proteases are involved in programmed cell death, but their role in metabolic diseases, inflammation and immunity has been of interested. Discover the latest research on caspases in metabolic diseases here.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptotic Caspases

Apoptotic caspases belong to the protease enzyme family and are known to play an essential role in inflammation and programmed cell death. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.